Expand existing large scale, open-science molecular profiling efforts by:
- Increasing the bandwidth for the generation and analysis of high-quality molecular data (genetics and epigenetics, transcriptomics, proteomics, metabolomics, lipidomics, glycomics, exposome, etc.) from human tissues and cell lines.
- Investing in the development of methods for multi-scale modeling across -omics data-types.
- Ensuring that diverse cohorts and special populations are included and prioritized in these efforts.
Provide supplemental funding to at least 6 existing projects/programs that are generating high-dimensional on human aging cohorts to close key molecular data gaps, including molecular profiling for post-translational modification, methods development for multi-scale modeling, and inclusion of samples from diverse cohorts and special populations.
Ensure that existing and newly funding projects continue to operate under open science principles.
Summary of Key Accomplishments
Through the Accelerating Medicines Partnership for Alzheimer’s Disease (AMP-AD), the HABS-HD (Health and Aging Brain Study- Health Disparities) and ABC-DS (Alzheimer’s Biomarkers Consortium - Down Syndrome) consortia, NIA is supporting the generation of various types of molecular data from biosamples collected from diverse as well as special populations (African American and Latino Cohorts; individuals with Down Syndrome) known to be at higher risk of AD/dementia. These programs operate under open science principles, i.e., the data are being made available rapidly to the greater research community in the academic and biotech/industry sectors. NIA supports the development of advanced analytical methods that will use these biological datasets to build mathematical models of the disease that reflect the various mechanisms of disease risk and resilience across different populations.
This information is current as of March 2022.
- Research Implementation Area
- Population Studies and Precision Medicine
- RFA-AG-13-013: Interdisciplinary Approach to Identification and Validation of Novel Therapeutic Targets for Alzheimer's Disease (R01)
- RFA-AG-15-010: Interdisciplinary Research to Understand the Vascular Contributions to Alzheimer's Disease (R01)
- RFA-AG-15-011: Biomarkers of Alzheimer’s Disease in Down Syndrome (R01)
- RFA-AG-17-061: Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer’s Disease Risk (R01)
- RFA-AG-18-013: Continuation of the AMP AD Target Discovery and Preclinical Validation Consortium
- RFA-AG-18-014: Limited Competition: Data Coordinating Center for the Accelerating Medicines Partnership Target Discovery and Preclinical Validation Consortium AMP AD (U24)
Research Programs and Resources
- Alzheimer’s Biomarkers Consortium- Down Syndrome (ABC-DS)
- Alzheimer’s Disease Sequencing Project (ADSP)
- AMP AD – Target Discovery and Preclinical Validation
- AMP-AD 2.0 Precision Medicine Approach to Target and Biomarker Discovery
- Molecular Mechanisms of the Vascular Etiology of Alzheimer's Disease (M²OVE-AD) Consortium
- Next Generation Translational Proteomics for Alzheimer’s Disease and Related Dementias